Perflutren Lipid Microcpheres

Phase 2Small molecule

Perflutren Lipid Microcpheres is one of 123 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Liver CancerActive, not recruiting

Breast CancerActive, not recruiting

Bile Duct CancerActive, not recruiting

Kidney CancerPhase 1

Active, not recruiting

Liver CancerPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Bile Duct CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Halaven

Eisai

Preclinical

38 3

Tecentriq

Roche

Preclinical

36 4

Perflutren Lipid Microcpheres

TThomas Jefferson University

Phase 2

2 5

MS Contin

Merck & Co.

Preclinical

2 6

Avastin

Roche

Preclinical

4 7

Nubain

AAultman Health Foundation

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer

Unknown status·TThomas Jefferson University·Phase 1·NCT04721886·25 enrolled

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

Completed·MM.D. Anderson Cancer Center·N/A·NCT02321527·21 enrolled

Liver Cancer1 trial

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Completed·TThomas Jefferson University·Phase 2·NCT03199274·104 enrolled

Bile Duct Cancer1 trial

Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

Completed·TThomas Jefferson University·Phase 2·NCT05328167·16 enrolled

Kidney Cancer1 trial

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT02671552

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Perflutren Lipid Microcpheres. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perflutren Lipid Microcpheres compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perflutren Lipid Microcpheres. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thomas Jefferson University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThomas Jefferson University

Perflutren Lipid Microcpheres

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Liver Cancer1 trial

Bile Duct Cancer1 trial

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News